India approves $1.9 billion Agila acquisition

US generics company Mylan wins go-ahead to buy Bangalore-based injectables business from India’s Strides Arcolab.

India has approved a $1.9 billion bid for pharmaceuticals company Agila Specialties, as the country strives to dispel its image as a hostile destination for foreign investors.

Mylan, a US company that makes generic drugs, signed an agreement to buy Agila from Strides Arcolab in late February, but the acquisition stumbled after one set of regulators complained that selling to a foreign buyer could affect the availability of important cancer drugs in India.


FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition